Weather , , 0°C

Rare Disease Genetic Testing Market Poised A Staggering Growth Worth $1.8 Billion By 2027 | Grand View Research, Inc.

 Breaking News
  • No posts were found

Rare Disease Genetic Testing Market Poised A Staggering Growth Worth $1.8 Billion By 2027 | Grand View Research, Inc.

May 07
10:24 2021
Rare Disease Genetic Testing Market Poised A Staggering Growth Worth $1.8 Billion By 2027 | Grand View Research, Inc.

Grand View Research, Inc. – Market Research And Consulting.
Key factors that are driving the rare disease genetic testing market growth include plummeting sequencing cost, expanding patient registry for rare disease, & launch of programs to advance in rare disease diagnosis.

The global rare disease genetic testing market size is expected to reach USD 1.8 billion by 2027 expanding at a CAGR of 10.8% over the forecast period, according to a new report by Grand View Research, Inc. Conventional test methods provide delayed diagnosis. Moreover, patients need to visit physicians to correctly identify a rare condition, leading to an increased healthcare spending. This has spurred the adoption of genetic test methods for accurate and timely identification of rare conditions.

Ongoing scientific advances in this area have created new opportunities for the companies to develop solutions that can impact the management of the rare condition. Collaborations are being undertaken not only across diverse medical and scientific domains but also with various stakeholder groups, such as researchers, patients, and regulators, for new test development, thereby driving the market.

For instance, in October 2018, PerkinElmer Genomics signed an agreement with Sanofi Genzyme to introduce a free genetic testing program called the Lantern Project. The initiative was designed for patients who have or are suspected of having, certain types of lysosomal storage disorders, including Gaucher disease. 

Browse full report with Table of Content @

Rare Disease Genetic Testing Market Report Highlights

 Neurological disorders accounted for the major revenue share in 2019 owing to availability of a substantial number of test offerings by various companies, such as Invitae and Centogene

 Furthermore, the National Institute of Neurological Disorders and Stroke supports research studies for a wide range of diseases, thereby positively impacting the segment growth

 Availability and adoption of NGS-based gene panels for cancer, neurologic disease, CVDs, and other rare disease testing has driven the NGS segment

 NGS has enabled rapid and cost-effective genetic testing by helping in determining the relevance of de novo and mosaic mutations

 It has also helped in detecting the wide phenotypic spectrum of genes, digenic inheritance, and presence of more than one rare condition in the same individual

 Thus, a significant decline in the cost of NGS has driven its adoption for molecular testing, contributing to the large share of molecular genetic tests

 Laboratories are engaged in conducting a substantial number of genetic tests. This includes labs that are accredited with CLIA for clinical cytogenetics, pathology, and chemistry, among other specialties

 Furthermore, regulatory bodies play a major role in the growth of this segment, as they help laboratories conduct effective and safe genetic testing, leading to their dominance as end-user of the market

 North America led the global market in 2019 owing to the presence of key research and diagnostic laboratories in U.S.

Get Sample Copy Of This Report @

Rare Disease Genetic Testing Market Segmentation

Grand View Research has segmented the global rare disease genetic testing market on the basis of disease type, technology, specialty, end use, and region:

Rare Disease Genetic Testing Disease Type Outlook (Revenue, USD Million, 2016 – 2027)

  • Neurological Disorders

  • Immunological Disorders

  • Hematology Diseases

  • Endocrine & Metabolism Diseases

  • Cancer

  • Musculoskeletal Disorders

  • Cardiovascular Disorders (CVDs)

  • Dermatology Disease

  • Others

Rare Disease Genetic Testing Technology Outlook (Revenue, USD Million, 2016 – 2027)

  • Next-Generation Sequencing (NGS)

    • Whole Exome Sequencing (WES)

    • Whole Genome Sequencing (WGS)

  • Array Technology

  • PCR-based Testing

  • FISH

  • Sanger Sequencing

  • Karyotyping

Rare Disease Genetic Testing Specialty Outlook (Revenue, USD Million, 2016 – 2027)

  • Molecular Genetic Tests

  • Chromosomal Genetic Tests

  • Biochemical Genetic Tests

Rare Disease Genetic Testing End-use Outlook (Revenue, USD Million, 2016 – 2027)

  • Research Laboratories & CROs

  • Diagnostic Laboratories

  • Hospitals & Clinics

Rare Disease Genetic Testing Regional Outlook (Revenue, USD Million, 2016 – 2027)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Spain

    • France

    • Italy

    • The Netherlands

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Singapore

    • Australia

    • South East Asia

  • Latin America

    • Brazil

  • Middle East & Africa

    • South Africa

List of Key Players of Rare Disease Genetic Testing Market:

  • Quest Diagnostics Inc.

  • Centogene N.V.

  • Invitae Corporation

  • 3billion, Inc.

  • Arup Laboratories

  • Eurofins Scientific

  • Strand Life Sciences

  • Ambry Genetics

  • Perkin Elmer, Inc.

  • Macrogen, Inc.

  • Baylor Genetics

  • Color Genomics, Inc.

  • Health Network Laboratories

  • Preventiongenetics

  • Progenity, Inc.

  • Coopersurgical, Inc.

  • Fulgent Genetics Inc.

  • Myriad Genetics, Inc.

  • Laboratory Corporation Of America Holdings

  • Opko Health, Inc.

Speak to Analyst @

About Grand View Research

Grand View Research is a market research and consulting company headquartered in San Francisco, which offers syndicated research reports, customized research reports, and consulting services to clients across a number of industries, including healthcare, materials, chemicals, energy, technology, and food and beverage, among others.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States

Related Articles


June 2021